Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
about
Eslicarbazepine acetate add-on for drug-resistant partial epilepsyA review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsyUpdate on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsyRecent treatment advances and novel therapeutic approaches in epilepsySafety and tolerability of perampanel: a review of clinical trial data.Pharmacokinetics and drug interactions of eslicarbazepine acetate.Update on treatment of partial onset epilepsy: role of eslicarbazepineEfficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.Clinical utility of eslicarbazepine: current evidence.Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampusTime to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpointEslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action.Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapyEvaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis.New developments in the treatment of partial-onset epilepsy.Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR® ) in adults with partial-onset seizures.Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses.Placebo-corrected efficacy of modern nonenzyme-inducing AEDs for refractory focal epilepsy: systematic review and meta-analysis.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Recent and future antiepileptic drugs and their impact on cognition: what can we expect?Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies.Drug-induced cerebellar ataxia: a systematic review.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.Eslicarbazepine acetate for the treatment of partial epilepsy.EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.[Anticonvulsant add-on therapy with Eslicarbazepine acetate : Results of the EPOS-study in adults in Germany].Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.
P2860
Q24234598-4FC990D6-C60A-4771-A65A-AB64DDF32E52Q24621327-77C6C884-58BF-476A-A207-65C5D4BDD3B9Q26745780-21EC733E-DCBA-4C58-B05C-2D6EE96D7FAEQ26824512-63AEA773-B7AD-4E99-B084-EE519782DDFFQ30597533-FF3BCC54-7007-43B3-A917-D8F37EDC5C95Q34276263-F8323BD3-E216-460B-ADA9-526ED958942FQ34329823-E1B3EF9E-1AB3-4195-9F08-B48C01622E9BQ34375311-47ABAB42-E6B1-414C-96C2-4A53BC8D0DE0Q35087964-67ECD674-F9E5-481F-B535-40181D3DB8DCQ35161125-39FD41EA-55EF-4BA9-A6C0-98711BFA2122Q35424907-2F8F459D-2213-44E6-AF59-10FEF958F873Q35531026-D93A2FBC-E75A-4086-B43E-5AE364691344Q35639962-312C22B7-1D6B-47D9-BB61-17D008B3F8CEQ35664957-81809A51-2467-4238-91E0-BC97150AA9DBQ35936036-09E70B34-A5C5-48B7-85A4-F9993A3B5C0EQ36284727-E0A9B00E-6C35-4344-A6E3-B882984863F5Q36337897-7BEEF8A1-7989-4FB3-8D0B-82042850DB7BQ37295962-AB8A4A36-F82C-490B-A4F0-6DAB18A16F53Q37680030-7A8C3118-7DD6-46DC-BD05-1AA73BF1D161Q37694387-BAA444C1-529F-4A9B-96D6-66F70BD8BC0FQ37950518-EC4BA7ED-F87E-4435-9463-D633655F32DAQ37957121-B0C3B4C2-B080-43F2-92FC-0CDF45AA9015Q37964697-1F0999F0-83B1-4461-8693-B2D55AED712AQ37968623-C82F444F-AAB5-44E3-B003-0CCC0872F19FQ37975526-A92D9471-C5C9-4FBA-B7D6-238DF0CAB89BQ37992162-6D715053-5D7A-4D8C-8710-EB9E07990FE4Q38014887-478E2918-8DA1-46CC-BB15-B6E11BF945ADQ38076077-6A1F4A58-B4B5-4111-AEC2-8EFE46B6A50EQ38223958-2E760E8A-173A-4513-9A2B-996F1E39BB6FQ38259757-F75C6430-8910-48D7-B9C9-A52580139A27Q38267726-C5235920-7627-4066-9D03-385517E9567BQ38367761-0E8547CD-B7D8-438B-AE4D-2102DFAC05E6Q38542064-4984CC2B-DA4C-434C-BC13-36460BABD584Q38656011-AE7B6082-EDF3-4AD8-819B-22B2DA68CA93Q38826584-BEA96BC0-11F0-4597-A7BB-30FB0D67366DQ39116160-2676D9F8-5561-4C27-9F78-099219626078Q39456360-D29644A9-825B-4B17-8C61-095E6DD51848Q40611807-6EEC2364-985D-47CA-BE73-105DE0540F25Q44062629-6AC20921-C34B-40F2-B9EC-39E15DE782FBQ44168300-5DED1DD1-6353-456D-B989-C04AF58ACF3F
P2860
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
@en
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
@nl
type
label
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
@en
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
@nl
prefLabel
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
@en
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
@nl
P2093
P1433
P1476
Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
@en
P2093
A A Gabbai
A Hufnagel
E Ben-Menachem
P304
P356
10.1016/J.EPLEPSYRES.2010.01.014
P577
2010-03-17T00:00:00Z